Stealth BioTherapeutics Corp (NASDAQ:MITO) – Equities research analysts at Jefferies Financial Group issued their FY2023 earnings per share estimates for shares of Stealth BioTherapeutics in a report issued on Thursday, August 15th. Jefferies Financial Group analyst M. Raycroft expects that the company will earn ($0.01) per share for the year.
Stealth BioTherapeutics (NASDAQ:MITO) last released its earnings results on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.04.
MITO opened at $10.79 on Monday. The stock has a market cap of $423.51 million and a PE ratio of -7.65. The company has a 50 day moving average price of $12.17. Stealth BioTherapeutics has a 52 week low of $10.70 and a 52 week high of $20.99.
A hedge fund recently bought a new stake in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC acquired a new stake in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned about 0.18% of Stealth BioTherapeutics at the end of the most recent quarter. 0.73% of the stock is currently owned by institutional investors and hedge funds.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.